BioSpace News Archive

Abveris will be launching a sister company, AbX Biologics, with an exclusive focus on therapeutic antibody discovery services.

In connection with the acquisition, FHP retained Des Moines, Iowa based Life Care Services, as their management firm.

The 3rd AI for Good Global Summit, a leading United Nation platform for multilateral dialogue on Artificial Intelligence, was kicked off in Geneva, Switzerland, May 28-31.

BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced that the first-in-human Phase I/IIa study with DuoBody-PD-L1x4-1BB has been initiated.

On June 15, the second Chengdu International Cosmetic Medicine Industry Conference and the “Capital of Cosmetic Medicine” summit forum, cosponsored by Chengdu People’s Government, Sichuan Health Committee, and Chinese Association of Plastics and Aesthetics, officially opened at International Convention Center, Century City, Chengdu, and the conference will last till June 17.

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced the appointment of Jeffrey Calabrese, CPA, as Director of Accounting, reporting to Christopher Staten, Aerie’s Vice President of Finance.

Reference is made to the stock exchange notice published by Nordic Nanovector ASA on 31 May 2019 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of RSUs.

Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term

A news release detailing the quarterly results will be made available at 6:00 a.m. Eastern Time the morning of the conference call.

The Conference will explore the latest developments in the European market.